



Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number **10/554,043**

Filing Date **August 10, 2006**

First Named Inventor **PLAVEC, IVAN**

Group Art Unit **1631**

Examiner Name **Unassigned**

Total Number of Pages in This Submission

Attorney Docket Number **SEEK-006**

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☒ Information Disclosure Statement
- ☒ USPTO Form SB08A
- ☒ 19 cited references
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Certified Copy of Priority Documents
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Return postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent
(Reg. No.)

**PAMELA J. SHERWOOD, 36,677
BOZICEVIC, FIELD & FRANCIS, LLP**

Signature


Date

March 28, 2007

EXPRESS MAIL LABEL NO. EV 954 013 435 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INFORMATION DISCLOSURE STATEMENT  Address to: Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	SEEK-006
	First Named Inventor	PLAVEC, IVAN
	Application Number	10/554,043
	Confirmation No.	8308
	Filing Date	August 10, 2006
	Group Art Unit	1631
	Examiner Name	Unassigned
	Title:	"METHODS FOR CHARACTERIZING SIGNALING PATHWAYS AND COMPOUNDS THAT INTERACT THEREWITH"

Dear Examiner:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited foreign and non-patent literature references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement under 37 C.F.R. §1.97 is not to be construed as a representation that: (i) a search has been made, (ii) additional information material to the examination of this application does not exist, (iii) the information, protocols, results and the like reported by third parties are accurate or enabling or (iv) any one of the above references constitutes prior art to the present application.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. However, if it is determined that fees are required in connection with the filing of this document, the Commissioner is hereby authorized to charge any necessary fees, or alternatively, credit any overpayment to our Deposit Account No. 50-0815, Order No. SEEK-006.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: March 28, 2007

By: 

Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



PTO/SB/08a (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known	
	Application Number	10/554,043		
	Filing Date	August 10, 2006		
	First Named Inventor	PLAVEC, IVAN		
	Art Unit	1631		
	Examiner Name	Unassigned Clow		
Sheet	1	of	2	Attorney Docket Number
				SEEK-006

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication or Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US - 4,568,649		02-04-1986	Bertoglio-Matte	
		US - 5,569,588		10-29-1996	Ashby et al.	
		US - 5,631,153		05-20-1997	Capecchi et al.	
		US - 5,777,888		07-07-1998	Rine et al.	
		US - 5,994,076		11-30-1999	Chenchik et al.	
		US - 6,004,755		12-21-1999	Wang	
		US - 6,013,437		01-11-2000	Luria et al.	
		US - 6,148,830		11-14-2000	Friend et al.	
		US- 6,656,695 B2		12-02-2003	Berg et al.	
		US - 6,763,307		07-13-2004	Berg et al.	
		USSN 60/465,152		04-23-2003	Plavec et al.	
		USSN 10/220,999		09-11-2003	Berg et al.	
		USSN 10/236,558		09-05-2002	Plavec et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
		WO	96/23075	08-01-1996	Boggs		
		WO	95/06132	03-02-1995	Andrianopoulos		
		WO	98/51810	11-19-1998	Olsen		
		WO	00/00600	01-06-2000	Chang		
		WO	01/67103 A1	09-13-2001	Berg et al.		
		WO	03/023573 A2	03-20-2003	Berg et al.		

Examiner Signature	/Lori Clow/	Date Considered	02/26/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/554,043		
		Filing Date	August 10, 2006		
		First Named Inventor	PLAVEC, IVAN		
		Art Unit	1631		
		Examiner Name	Unassigned Clow		
Sheet	2	of	2	Attorney Docket Number	SEEK-006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALTSCHUEL, et al., "Issues in searching molecular sequence databases," (1994) <i>Nature Genetics</i> , 6:119-129	
		BLACKSTOCK, et al., "Proteomics: Quantitative and physical mapping of cellular proteins," (1999) <i>Tibtech</i> , 17:121-127	
		COLLINS, et al., "Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers," (1995) <i>FASEB</i> , 9:899-909	
		GIULIANI, et al., "Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2," (1999) <i>Journal of Cell Science</i> , 112 (Pt 15):2597-606	
		HATZIMANIKATIS, et al., "Proteomics: Theoretical and experimental considerations," (1999) <i>Biotechnol.</i> , 15:312-318	
		HAUSNER, et al., "The comparative growth assay: Examining the interplay of anti-cancer agents with cells carrying single gene alterations," (1999) <i>Neoplasia, Doyma</i> , 1(4):356-367	
		HELLER, et al., "Discovery and analysis of inflammatory disease-related genes using CDNA microarrays," (1997) <i>PNAS</i> , 94:2150-2155	
		KONSTANTOPOULOS, et al., "Endothelial P-selectin and VCAM-1: each can function as primary adhesive mechanisms for T cells under conditions of flow," (1997) <i>J of Leukocyte Biology</i> , 61:179-187	
		MAY, et al., "Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells," (1996) <i>British Journal of Pharmacology</i> , 118(7):1761-1771	
		MULLNER, et al., "Proteomics: A new way for drug target discovery," (1998) <i>Arzneim-Forsch</i> , 48(1):93-95	
		NELLEN, et al., "What makes an mRNA anti-sense-itive?," (1993) <i>TIBS</i> , 18:419-423	
		RICE, et al., "Development of a high volume screen to identify inhibitors of endothelial cell activation," (1996) <i>Anal Biochemistry</i> , 241:254-259	
		SHINKAI, et al, "A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity eosinophils," (1999) <i>J of Immunology</i> , 163:1602-1610	

Examiner Signature	/Lori Clow/	Date Considered	02/26/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LC/